IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v112y2013i3p285-296.html
   My bibliography  Save this article

Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time

Author

Listed:
  • Sandmann, Frank G.
  • Franken, Margreet G.
  • Steenhoek, Adri
  • Koopmanschap, Marc A.

Abstract

To investigate the desirability and feasibility of a cyclic reimbursement process to address uncertainty accompanying initial decision making.

Suggested Citation

  • Sandmann, Frank G. & Franken, Margreet G. & Steenhoek, Adri & Koopmanschap, Marc A., 2013. "Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time," Health Policy, Elsevier, vol. 112(3), pages 285-296.
    • Handle: RePEc:eee:hepoli:v:112:y:2013:i:3:p:285-296
    DOI: 10.1016/j.healthpol.2013.03.006
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851013000705
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2013.03.006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Andrew Yu & Scott Johnson & Si-Tien Wang & Pavel Atanasov & Jackson Tang & Eric Wu & Jingdong Chao & Parvez Mulani, 2009. "Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease," PharmacoEconomics, Springer, vol. 27(7), pages 609-621, July.
    2. James Spalding & Joel Hay, 2006. "Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 24(12), pages 1221-1232, December.
    3. Zhimei Liu & Quan Doan & Jennifer Malin & Robert Leonar, 2009. "The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 193-205, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wun-Yu You & Tzu-Pei Yeh & Kwo-Chen Lee & Wei-Fen Ma, 2020. "A Preliminary Study of the Comfort in Patients with Leukemia Staying in a Positive Pressure Isolation Room," IJERPH, MDPI, vol. 17(10), pages 1-10, May.
    2. Boon, Wouter & Martins, Luis & Koopmanschap, Marc, 2015. "Governance of conditional reimbursement practices in the Netherlands," Health Policy, Elsevier, vol. 119(2), pages 180-185.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hussain Abdulrahman Al-Omar & Hadeel Magdy Sherif & Ahmed Yaccob Mayet, 2019. "Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-15, October.
    2. Nadia Pillai & Mark Dusheiko & Bernard Burnand & Valérie Pittet, 2017. "A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-22, October.
    3. Stefan Scholz & Thomas Mittendorf, 2014. "Modeling rheumatoid arthritis using different techniques - a review of model construction and results," Health Economics Review, Springer, vol. 4(1), pages 1-16, December.
    4. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.
    5. Kelly Fust & Xiaoyan Li & Michael Maschio & Guillermo Villa & Anju Parthan & Richard Barron & Milton C. Weinstein & Luc Somers & Caroline Hoefkens & Gary H. Lyman, 2017. "Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma," PharmacoEconomics, Springer, vol. 35(4), pages 425-438, April.
    6. Monia Marchetti & Nicola Liberato & Antonio Sabatino & Gino Corazza, 2013. "Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 853-861, December.
    7. James Signorovitch & Eric Wu & Andrew Yu & Charles Gerrits & Evan Kantor & Yanjun Bao & Shiraz Gupta & Parvez Mulani, 2010. "Comparative Effectiveness Without Head-to-Head Trials," PharmacoEconomics, Springer, vol. 28(10), pages 935-945, October.
    8. Christine Nguyen & Mark Bounthavong & Margaret Mendes & Melissa Christopher & Josephine Tran & Rashid Kazerooni & Anthony Morreale, 2012. "Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 30(7), pages 575-593, July.
    9. Bradford Hirsch & Gary Lyman, 2012. "Pharmacoeconomics of the Myeloid Growth Factors," PharmacoEconomics, Springer, vol. 30(6), pages 497-511, June.
    10. Saara Huoponen & Marja Blom, 2015. "A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-23, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:112:y:2013:i:3:p:285-296. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.